Merck Serono Initiates Phase III Trial Of Safinamide In Early Parkinson’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck KGaA has initiated a new Phase III study evaluating the alpha aminoamide derivative safinamide in patients with early Parkinson's disease with changes to dosing and the primary efficacy endpoint informed by the results of an earlier failed trial
You may also be interested in...
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.
Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval
The company received two complete response letters from the US FDA for the CD20xCD3 bispecific antibody odronextamab due to clinical trial requirements for accelerated approval.